search
CovModDrugDiscov
Trends
- 1Darrin McKenzie presents automated covalent drug discovery platform●Interesting talk by Darrin McKenzie at # CovModDrugDiscov . He talked about, how they set up an automated platform to st
Darrin McKenzie spoke at the CovModDrugDiscov conference about an automated platform his team built to study protein expression levels and cysteine engagement in living cells. The work targets covalent inhibitor drug discovery, combining chemical proteomics and chemical biology approaches. Attendees described the talk as interesting, with the automation of these assays drawing particular attention from researchers in drug discovery.
- 2Steven Gygi opens day two of covalent drug discovery meeting●The 2nd day of # CovModDrugDiscov gets on the way with an inspiring talk by Steven Gygi. He talked about the power of TM
The second day of the CovModDrugDiscov conference opened with an invited talk by Steven Gygi, a leading figure in proteomics. He presented how TMT multiplexing technologies enable high-throughput, residue-specific chemoproteomics, a method relevant to identifying targets of covalent inhibitor drugs. Attendees described the talk as inspiring, and the meeting continues to draw discussion across chemistry and chemical biology communities.
- 3AstraZeneca talk highlights computational drug discovery for KRAS G12C●Interesting talk by Michael Bodnarchuk from Astra Zeneca at # CovModDrugDiscov . He talked about the use of computationa
Michael Bodnarchuk of AstraZeneca spoke at the CovModDrugDiscov conference about using computational tools to discover covalent, brain-penetrant KRAS G12C inhibitors. The approach combines covalent chemistry with computational methods to target the KRAS G12C mutation, including drug candidates capable of crossing the blood-brain barrier. Researchers in the drug discovery and chemistry community are sharing notes on the presentation.
- 4Federica Raguseo presents phenotype-first covalent drug discovery approach●Interesting talk by Federica Raguseo at # CovModDrugDiscov . She talked about a phenotype-first approach to covalent dru
Researcher Federica Raguseo gave a talk at the CovModDrugDiscov conference on a phenotype-first approach to covalent drug discovery, using the enzyme TYMS (thymidylate synthase) as a case study. The work is associated with a recent bioRxiv preprint. Observers in the drug discovery community have highlighted the talk as an interesting example of phenotypic screening guiding the development of covalent inhibitors.
- 5Covalent Modification in Drug Discovery Conference Opens with Bogyo Talk●The first day of # CovModDrugDiscov comes to an end with an exciting talk by Matt Bogyo. He talked about covalent probes
The first day of the CovModDrugDiscov conference closed with a talk by Matt Bogyo on covalent probes that can visualize bacterial infections and tumors. The approach has reportedly advanced to phase 3 studies for fluorescence-guided surgery, a development attendees highlighted as an exciting step toward clinical use. The presentation marked the end of the opening day of the meeting.
- 6David Heppner presents covalent inhibitor research at drug discovery conference●Great talk by David Heppner at # CovModDrugDiscov . He gave exciting insights into rigorously characterizing # CovalentI
David Heppner delivered a talk at the CovModDrugDiscov conference, presenting work on rigorously characterizing covalent inhibitors using crystal structures and kinetic data. His presentation drew on research using epidermal growth factor receptor as a model drug target, published in an ACS journal. Attendees praised the talk, calling the insights into covalent inhibitor design exciting and highlighting the value of combining structural biology with kinetic characterization.
- 7Covalent Modulation in Drug Discovery Conference opens with Roche talk●The Covalent Modulation in Drug Discovery Conference # CovModDrugDiscov is off to a great start with an insightful talk
The Covalent Modulation in Drug Discovery Conference has begun, opening with a talk by Matt Bilyard of Roche. He outlined how the company selects targets for covalent drug discovery and identifies and develops covalent binders. The presentation was described as insightful, with attendees sharing early reactions from the event online.